Mandate

Vinge advises the founders of Future Media Group in conjunction with the sale to Caybon

Vinge has advised the founders Rikard Virta, Linus Wennerström and Johan Oscarsson as well as the other shareholders in conjunction with the sale of Future Media Group AB to Caybon.

Future Media Group specialises in helping media owners and growth companies to generate new revenue streams through business development, product development and sales. In close co-operation with its partners, new advertising formats, media solutions and marketing concepts are developed, and the solutions to the correct target groups are prepared in conjunction with the different sales organisations specialising in different types of products and customer segments.

Future Media Groups current partners currently include large media groups such as Bonnier and Stampen, as well as niche actors such as Preglife (the Nordic Region’s leading pregnancy app) and the digital veterinary service, Firstvet. The company has offices in Stockholm and Oslo and employs approximately 100 persons. 

Vinges team has primarily consisted of Jonas JohanssonCarl SanderEllinor Wargenbrant and Linus Adolfsson (M&A), as well as Sara Dahlros Sköld and Ellinore Boström Andersson (VDR).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025